Evoque (tricuspid valve replacement system)

2023: Product Announcement

On October 19, 2023, Edwards Lifesciences announced the release of a system called Evoque to replace the tricuspid valve. The product is intended for the treatment of tricuspid regurgitation - one of the most common heart defects.

The tricuspid valve (tricuspid valve) is located between the right atrium and the right ventricle of the heart. It consists of three connective tissue plates that, during right ventricular systole, prevent regurgitation (reverse flow) of blood to the right atrium. In tricuspid regurgitation, the ventricular septal valve does not close completely, leading to reverse blood flow to the right atrium. The causes of the disease can be different: these are, in particular, congenital anomalies, acquired defects, heart failure, infectious diseases, etc.

Evoque Tricuspid Valve Replacement System

The Evoque product consists of a nitinol self-expanding frame, an in-ring sealing skirt and fabric petals made of bovine pericardial fabric. The artificial valve is available in three sizes. The solution is implanted with a minimally invasive delivery system in which a doctor places a thin tube through a vein in the leg to reach the heart and perform a valve replacement procedure.

Evoque is said to be the world's first transcatheter valve replacement system to receive regulatory approval for the treatment of tricuspid regurgitation. The product received the CE sign (Conformité Européenne), confirming compliance with the basic requirements of directives and harmonized standards of the European Union. According to Edwards, the Evoque system is able to help many patients who previously did not have suitable treatment options. Artificial valve allows improving quality of life of people suffering from tricuspid regurgitation.^[1]

Notes